These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24490745)

  • 21. Does intensive glycemic control improve cardiovascular outcomes?
    Pendergrass M
    Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):529. PubMed ID: 18806805
    [No Abstract]   [Full Text] [Related]  

  • 22. 2008 resource guide. Type 2 drugs. There are now six classes of diabetes pills and several combination oral meds. Each has a different way of helping you control your diabetes.
    McCarren M
    Diabetes Forecast; 2008 Jan; 61(1):RG7-9. PubMed ID: 18290287
    [No Abstract]   [Full Text] [Related]  

  • 23. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.
    Harrigan RA; Nathan MS; Beattie P
    Ann Emerg Med; 2001 Jul; 38(1):68-78. PubMed ID: 11423816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
    Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
    Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment.
    Gore MO; McGuire DK
    Diab Vasc Dis Res; 2012 Apr; 9(2):85-8. PubMed ID: 22496441
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes.
    DeSouza C; Fonseca V
    Nat Rev Drug Discov; 2009 May; 8(5):361-7. PubMed ID: 19404311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs?
    Low Wang CC; Everett BM; Burman KD; Wilson PWF
    Circulation; 2019 Apr; 139(14):1741-1743. PubMed ID: 30933621
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?
    John M; Gopalakrishnan Unnikrishnan A; Kalra S; Nair T
    Indian Heart J; 2016; 68(4):564-71. PubMed ID: 27543483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Is hypoglycemia dangerous in type 2 diabetes?].
    Grimaldi A
    Rev Prat; 2015 Sep; 65(7):903-6. PubMed ID: 26619722
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardiovascular safety of anti-diabetic drugs.
    Kumar R; Kerins DM; Walther T
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):32-43. PubMed ID: 27533060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.
    Stähli BE; Gebhard C; Tardif JC
    Curr Cardiol Rep; 2015 Jul; 17(7):608. PubMed ID: 26031672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of diabetes: Crossing to the other side.
    Skliros NP; Vlachopoulos C; Tousoulis D
    Hellenic J Cardiol; 2016; 57(5):304-310. PubMed ID: 27687958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Quality of healthcare in type 2 diabetes mellitus in Spain].
    Soriguer F; Ruiz de Adana MS
    Med Clin (Barc); 2012 May; 138(12):522-4. PubMed ID: 22118976
    [No Abstract]   [Full Text] [Related]  

  • 34. Whence and whither the fixed-dose combination?
    Bailey CJ
    Diab Vasc Dis Res; 2005 May; 2(2):51-3. PubMed ID: 16305058
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus.
    Joffe HV; Parks MH; Temple R
    Rev Endocr Metab Disord; 2010 Mar; 11(1):21-30. PubMed ID: 20195772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drugs and diabetes: understanding the new breed of cardiovascular safety trials.
    Adler AI
    Lancet Diabetes Endocrinol; 2013 Nov; 1(3):175-7. PubMed ID: 24622361
    [No Abstract]   [Full Text] [Related]  

  • 37. Is glucose control important for prevention of cardiovascular disease in diabetes?
    Mannucci E; Dicembrini I; Lauria A; Pozzilli P
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S259-63. PubMed ID: 23882055
    [No Abstract]   [Full Text] [Related]  

  • 38. Type 2 Diabetes Medication Review.
    Sterrett JJ; Bragg S; Weart CW
    Am J Med Sci; 2016 Apr; 351(4):342-55. PubMed ID: 27079339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome results renew debate about diabetes drug development.
    Mullard A
    Lancet Diabetes Endocrinol; 2013 Nov; 1(3):179-80. PubMed ID: 24622363
    [No Abstract]   [Full Text] [Related]  

  • 40. Controlling diabetes. Drug choices for blood sugar.
    Mayo Clin Health Lett; 2014 Sep; 32(9):1-3. PubMed ID: 25233542
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.